APLT - NASDAQ

Applied Therapeutics, Inc.

Applied Therapeutics, Inc.

APLTยทNASDAQ

$0.91

+0.0000%
HealthcareBiotechnology

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$131.07M
EPS-0.7600
P/E Ratio-1.13
Earnings Date11/13/2025
Applied Therapeutics, Inc.

Applied Therapeutics, Inc. Fair Value Envelope

APLT ยท NASDAQ

Our analysis suggests that APLT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $0.9101, this represents a potential HIDDEN relative to our calculated worth for Applied Therapeutics, Inc..

HIDDEN
Intrinsic Value
Current Price: $0.9101

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$72.6M
+ Cash & Equivalents$79.4M
Firm Value$6.8M
- Debt$2.8M
Equity Value$4.0M
/ Shares Outstanding144,012,125B
DCF Value$0
OVERVALUED BY 97%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$42.2M
-$21.1M
-$10.5M
-$5.3M
-$2.6M
-$1.3M
-$658.6K
-$329.3K
-$164.7K
-$82.3K
Maintenance CapEx
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
Owner Earnings
-$42.2M
-$21.1M
-$10.5M
-$5.3M
-$2.6M
-$1.3M
-$658.6K
-$329.3K
-$164.7K
-$82.3K
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$39.0M
-$18.1M
-$8.4M
-$3.9M
-$1.8M
-$830.1K
-$384.3K
-$177.9K
-$82.4K
-$38.1K
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your APLT research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.